Actively Recruiting
Study of Sonrotoclax, Zanubrutinib, and CD20mab Combination Therapy for Untreated Mantle Cell Lymphoma Patients Phase 2, Multi-center, Open-label Trial
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2025-05-11
30
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination of sonrotoclax, zanubrutinib, and CD20 monoclonal antibody CD20mab in patients with untreated Mantle Cell Lymphoma MCL. This open-label, multi-center, single-arm Phase 2 study aims to explore a chemo-free immunotherapy regimen for newly diagnosed MCL patients who may not tolerate traditional chemotherapy well. The study seeks to balance treatment effectiveness and safety in this patient population. Participants will receive sonrotoclax orally at a dose of 320 mg once daily following a ramp-up schedule, zanubrutinib orally at a total daily dose of 320 mg, and CD20mab, recommended as rituximab at 375 mgm2, administered from cycle 1 to cycle 12. Each treatment cycle lasts 28 days, and the regimen is designed to be given over 12 cycles. Other CD20 monoclonal antibodies may also be used as per protocol. During the study, participants will be monitored for treatment response, including complete response rate at the end of cycle 12. Researchers will also evaluate overall response rate up to cycle 36 and overall survival for up to 36 months. Assessments will include clinical evaluations, laboratory tests to monitor organ function and blood counts, and safety monitoring throughout treatment and follow-up. Informed consent and adherence to contraceptive measures for participants of child-bearing potential are required for participation.
CONDITIONS
Brief Title
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
Research Team
H
Huilai Zhang, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here